[CLDX] Celldex Therapeutics, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Biotechnology: In Vitro & In Vivo Diagnostic Substances

Market Capitalization: 442.27 M

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 3.76 Change: 0.15 (4.16%)
Ext. hours: Change: 0 (0%)

chart CLDX

Refresh chart

Strongest Trends Summary For CLDX

CLDX is in the medium-term up 66% in 3 months and up 849% above S&P in 1 year. In the long-term down -89% below S&P in 8 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Celldex Therapeutics, Inc., a biopharmaceutical company, focuses on the development, manufacture, and commercialization of novel therapeutics for human health care primarily in the United States. Its lead drug candidates include rindopepimut (CDX-110), a targeted immunotherapeutic in a pivotal Phase III study for the treatment of front-line glioblastoma and a Phase II study for the treatment of recurrent glioblastoma; and Glembatumumab vedotin (CDX-011) is a targeted antibody-drug conjugate in a randomized study for the treatment of triple negative breast cancer. The company also has various earlier stage drug candidates in clinical development, including varlilumab (CDX-1127), a fully human therapeutic monoclonal antibody for cancer indications; CDX-301, an immune cell mobilizing agent and dendritic cell growth factor; and CDX-1401, a targeted immunotherapeutic aimed at antigen presenting cells for cancer indications. Its preclinical product candidate includes CDX-014, a human monoclonal antibody-drug conjug

Fundamental Ratios
Shares Outstanding98.72 M EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters -17.91% Sales Growth - Q/Q-67.1% P/E
P/E To EPS Growth P/S120.97 P/BV1.18 Price/Cash Per Share1.23
Price/Free Cash Flow-4.27 ROA-29.03% ROE-31.51% ROI
Current Ratio17.22 Quick Ratio Long Term Debt/Equity Debt Ratio0.06
Gross Margin Operating Margin-3334.85% Net Profit Margin-3237.17% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities191.76 M Cash From Investing Activities-65.03 M Cash From Operating Activities-32.59 M Gross Profit
Net Profit-30.17 M Operating Profit-30.98 M Total Assets407.7 M Total Current Assets364.13 M
Total Current Liabilities21.15 M Total Debt Total Liabilities32.15 M Total Revenue490 K
Technical Data
High 52 week10.36 Low 52 week0.41 Last close5.81 Last change-1.86%
RSI27.32 Average true range2.87 Beta1.39 Volume1.44 M
Simple moving average 20 days-10.03% Simple moving average 50 days18.97% Simple moving average 200 days108.95%
Performance Data
Performance Week-0.85% Performance Month23.55% Performance Quart22.57% Performance Half1065.5%
Performance Year146.19% Performance Year-to-date95.72% Volatility daily14.15% Volatility weekly31.65%
Volatility monthly64.86% Volatility yearly224.69% Relative Volume247.49% Average Volume3.12 M
New High New Low

News

2019-03-08 11:04:04 | Celldex CLDX Q4 Loss Narrower than Expected, Sales Beat

2019-03-08 07:45:00 | Celldex Therapeutics' Cost-Cutting and Reverse Stock Split Help Keep It Rolling

2019-03-07 20:39:47 | Edited Transcript of CLDX earnings conference call or presentation 7-Mar-19 9:30pm GMT

2019-03-07 19:44:13 | Celldex Therapeutics, Inc CLDX Q4 2018 Earnings Conference Call Transcript

2019-03-07 16:01:00 | Celldex Provides Corporate Update and Reports Full Year 2018 Results

2019-03-07 07:48:00 | Daily Biotech Pulse: Allergan's Depression Drug Flunks Late-Stage Trial, Apellis Offering, ShockWave Medical IPO

2019-02-22 17:50:10 | Celldex Therapeutics CLDX Stock Sinks As Market Gains: What You Should Know

2019-02-20 08:25:00 | Analysis: Positioning to Benefit within Applied Materials, MRC Global, Meritor, Celldex Therapeutics, Quaker Chemical, and Cubic — Research Highlights Growth, Revenue, and Consolidated Results

2019-02-14 10:45:03 | The Zacks Analyst Blog Highlights: BioDelivery, Cytokinetics, Celldex, Aduro and Aeterna

2019-02-13 08:36:01 | 5 Tiny Biotech Stocks With Superb Growth Potential

2019-02-11 12:26:32 | The Celldex Reverse Stock Split: What Investors Need To Know

2019-02-11 09:55:00 | Biotech Stocks To Watch

2019-02-08 11:45:00 | Celldex Therapeutics Announces Reverse Stock Split

2019-02-05 09:20:00 | 4 Healthcare Stocks The Market is Watching on Tuesday 2/5/19

2019-02-05 08:30:00 | Biotech Stocks to Watch

2019-02-04 14:35:00 | These 4 Tech Stocks Could Set February Highs

2019-01-29 08:30:00 | Cannabis and Biotech Stocks that Could Explode

2019-01-23 08:30:00 | Best Ways to Play Biotech Rally

2019-01-21 08:30:00 | A Biotech Play You Can't Afford To Miss

2018-12-21 20:15:00 | Here's Why Celldex Therapeutics Sank on Friday

2018-12-10 12:24:00 | Why Celldex Therapeutics Is Jumping Today

2018-11-26 08:35:00 | Analysis: Positioning to Benefit within Celldex Therapeutics, InnSuites Hospitality Trust, Keryx Biopharmaceuticals, EMX Royalty, FTE Networks, and Xinyuan Real Estate — Research Highlights Growth, Revenue, and Consolidated Results

2018-11-10 08:01:00 | Celldex Presents Emerging MerTK Antibody Program at the Society for Immunotherapy of Cancer’s 33rd Annual Meeting

2018-11-09 08:12:01 | Celldex CLDX Q3 Earnings Beat Estimates, Revenues Miss

2018-11-09 08:01:00 | Celldex Presents Promising Interim Data from Phase 1 Study of Differentiated CD40 Agonist CDX-1140 at the Society for Immunotherapy of Cancer’s 33rd Annual Meeting

2018-11-08 17:48:00 | Here's Why Celldex Therapeutics, Inc. Surged on Thursday

2018-11-08 08:45:00 | Celldex Therapeutics Inc. Chugs Along in the 3rd Quarter Despite Challenges

2018-11-07 18:55:11 | Celldex Therapeutics CLDX Reports Q3 Loss, Lags Revenue Estimates

2018-11-07 17:49:50 | Celldex: 3Q Earnings Snapshot

2018-11-07 16:01:00 | Celldex Provides Corporate Update and Reports Third Quarter 2018 Results

2018-11-01 15:51:00 | Why Shares of Celldex Therapeutics, Inc. Sailed Higher Today

2018-10-22 15:18:00 | Why Celldex Therapeutics, Inc. Fell on Monday

2018-10-09 07:50:00 | Report: Developing Opportunities within Adamis Pharmaceuticals, Cass Information, Celldex Therapeutics, Par Pacific, Inovio Pharmaceuticals, and Liberty Global — Future Expectations, Projections Moving into 2018

2018-09-18 09:04:24 | What Investors Should Know About Celldex Therapeutics Inc’s NASDAQ:CLDX Financial Strength

2018-09-07 09:30:01 | Why Is Celldex CLDX Up 3.3% Since Last Earnings Report?

2018-08-23 15:03:00 | Why Celldex Therapeutics Inc. Shares Jumped on Wednesday

2018-08-23 08:00:00 | Today's Research Reports on Trending Tickers: Celldex Therapeutics and Inovio Pharmaceuticals

2018-08-09 10:04:02 | Celldex CLDX Q2 Earnings and Revenues Surpass Estimates

2018-08-09 06:30:00 | Celldex Therapeutics, Inc. Spending Cuts Help Preserve Cash in the 2nd Quarter

2018-08-08 19:50:11 | Celldex Therapeutics CLDX Reports Q2 Loss, Tops Revenue Estimates

2018-08-08 18:44:35 | Celldex: 2Q Earnings Snapshot

2018-08-08 16:01:00 | Celldex Provides Corporate Update and Reports Second Quarter 2018 Results

2018-08-08 14:30:00 | Celldex Therapeutics, Inc. to Host Earnings Call

2018-08-02 08:01:00 | Celldex to Report Second Quarter 2018 Financial Results and Host Corporate Update Call

2018-08-01 07:45:00 | Research Report Identifies Myriad Genetics, Celldex Therapeutics, Charles River Laboratories International, Louisiana-Pacific, Integrated Device Technology, and Beazer Homes with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement

2018-07-30 09:55:01 | What's in Store for Celldex CLDX This Earnings Season?

2018-07-27 07:35:00 | Initiating Free Research Reports on Celgene and Three Other Biotech Equities

2018-07-02 14:18:56 | How David Gardner's Biggest Losers Demonstrate Why Long-Term Investing Wins

2018-06-29 08:17:00 | Better Buy: Ziopharm Oncology, Inc. vs. Celldex Therapeutics

2018-06-21 08:00:00 | Complimentary Technical Snapshots on Celgene and Three More Biotech Stocks